Skip to main content

Table 3 Determination of MZH and PYH in different pharmaceutical formulations using the proposed methods using standard addition technique

From: Simultaneous analysis of two drugs used as supportive treatment for COVID-19: comparative statistical studies and analytical ecological appraisal

Drugs

MZH

PYH

Methods

RSM

IDW

FSD

Direct

Navoproxin plus® tabletsa (found% ± SD)

99.73 ± 0.88

99.58 ± 1.07

99.06 ± 0.83

100.14 ± 0.69

Navoproxin plus ® tabletsa standard addition (recovery% ± SD)b

100.18 ± 0.86

99.55 ± 0.78

99.70 ± 0.52

99.54 ± 0.93

Vomidoxine B6® tabletsa (found% ± SD)

100.09 ± 0.73

99.87 ± 1.22

99.15 ± 1.27

100.63 ± 0.61

Vomidoxine B6® tabletsa standard addition (recovery% ± SD)b

100.50 ± 1.08

99.36 ± 0.78

98.65 ± 0.41

99.53 ± 1.72

Dizirest B6® tabletsa (found% ± SD)

99.91 ± 1.01

99.66 ± 1.03

99.51 ± 0.90

101.06 ± 0.79

Dizirest B6® tabletsa standard addition (recovery% ± SD)b

99.19 ± 0.77

99.48 ± 1.22

100.13 ± 0.86

100.13 ± 1.05

  1. aNavoproxin plus, Vomidoxine B6 and Dizirest B6 claimed to contain 25 mg/mL of MZH and 50 mg/mL for PYH
  2. bAverage of five determinations